Bafna Pharmaceuticals share news, announcements and annual reports
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Bafna Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008 on BSE, Apr 2018 on NSE
Last close ₹457.00up ₹5.40 (1.20%)BSE ₹457.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹451.60.
29 Oct: open ₹460.60, high ₹460.60, low ₹457.00
52-week range of traded prices to 29 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,081 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 138.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 11.24
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 8,494
Bafna Pharmaceuticals disputes and clarifications
35 filed, newest first.
Apr 2026
15 Apr · Legal
The exchange asked on 13 Apr 2026
Mar 2026
24 Mar · Legal
The exchange asked on 23 Mar 2026
Jun 2021
28 Jun · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone auditors report not submitted. The response of the Company is awaited.28 Jun · Legal
Clarification - Financial Results
Mar 2021
18 Mar · Legal
The exchange asked on 17 Mar 2021
Dec 2020
7 Dec · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated Financial Results not submitted The response of the Company is awaited.7 Dec · Legal
Clarification - Financial Results
Sep 2020
23 Sep · Legal
The exchange asked on 22 Sep 2020
Jul 2020
14 Jul · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.14 Jul · Legal
Clarification - Financial Results
Aug 2019
14 Aug · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jun 2019
May 2019
29 May · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Jul 2018
20 Jul · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 18-Jul-2018, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified 3. Approval of resolution plan by the Tribunal or rejection, if applicable 4. Filing of resolution plan with the Tribunal 5. Number of resolution plan with the Tribunal 6. Brief particulars of invitation of resolution plans under section 25(2)(h) of Insolvency Code in the Form specified under regulation 36A(5) of IBBI (Insolvency Resolution Process for Corporate Persons) Regulations,2016 7. Prior or post-facto intimation of the meetings of Committee of Creditors 8. Appointment/Replacement of the Resolutions Professional 9. List of creditors as required to be displayed by the corporate debtor under regulation 13(2)(c) of the IBBI (Insolvency Resolution process for Corporate Persons ) Regulations.2016 10. Public announcement made pursuant to order passed by the Tribunal under section 13 of Insolvency Code 11. Admission of application by the Tribunal, along with amount of default or rejection or withdrawal, as applicable 12. Filing of application by financial creditors for initiation of CIRP against the corporate debtor, also specifying the amount of default 13. Filing of application by financial creditors for initiation of CIRP also specifying the amount of default The response of the Company is awaited.
Jun 2018
May 2018
29 May · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Oct 2017
6 Oct · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 06-Oct-2017, regarding "Outcome of Board Meeting held on October 06, 2017.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director).2. Brief profile (in case of appointment);The response of the Company is awaited.
Sep 2017
12 Sep · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 12-Sep-2017, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Aug 2017
9 Aug · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 08-Aug-2017, regarding " Outcome of Board Meeting held on August 08, 2017.On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.
Jan 2017
9 Jan · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 09-Jan-2017, informing that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under section 42 and 62 of the Companies Act, 2013 and other necessary approvals. It was further decided that the Company would notify through the newspapers the price of each equity share to be issued in lieu of Warrants calculated in accordance with Regulation 76(1) of Chapter of the SEBI ICDR Regulations on the basis of the Relevant Date for the benefit of the Members."On basis of above the Company is required to clarify following:1. Names of the investors;The response of the Company is awaited.5 Jan · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 05-Jan-2017, regarding "Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.On basis of above the Company is required to clarify following:1. Reasons for cancellation of the same.The response of the Company is awaited.
Nov 2016
12 Nov · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 11-Nov-2016, regarding "Bafna Pharmaceuticals Limited has informed the Exchange the Outcome of Board Meeting held on 11th November, 2016".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);The response of the Company is awaited.